1. Home
  2. INLX vs BRNS Comparison

INLX vs BRNS Comparison

Compare INLX & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intellinetics Inc.

INLX

Intellinetics Inc.

HOLD

Current Price

$5.45

Market Cap

26.4M

Sector

Technology

ML Signal

HOLD

Logo Barinthus Biotherapeutics plc

BRNS

Barinthus Biotherapeutics plc

HOLD

Current Price

$0.60

Market Cap

24.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INLX
BRNS
Founded
1996
2016
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.4M
24.1M
IPO Year
2013
2021

Fundamental Metrics

Financial Performance
Metric
INLX
BRNS
Price
$5.45
$0.60
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$4.00
AVG Volume (30 Days)
6.7K
38.9K
Earning Date
05-14-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$11,336.00
N/A
Revenue This Year
$16.86
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.25
$0.51
52 Week High
$13.66
$1.83

Technical Indicators

Market Signals
Indicator
INLX
BRNS
Relative Strength Index (RSI) 41.90 N/A
Support Level $5.45 N/A
Resistance Level $7.87 N/A
Average True Range (ATR) 0.21 0.00
MACD -0.01 0.00
Stochastic Oscillator 6.96 0.00

Price Performance

Historical Comparison
INLX
BRNS

About INLX Intellinetics Inc.

Intellinetics Inc is a document service and solutions software company serving both the small-to-medium business and governmental sectors. The company's digital transformation products and services are provided through two reporting segments: Software and Document Services. The Software segment consists of solutions involving software platforms, which allow customers to capture and manage all documents across operations such as scanned hard-copy documents and all digital documents including those from Microsoft Office 365, digital images, audio, video, and emails. The company's Document Services offerings aid clients as a part of their overall document to convert documents from one medium to another. Majority of revenue is from Document Services Segment.

About BRNS Barinthus Biotherapeutics plc

Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.

Share on Social Networks: